Soligenix gets orphan designation for SGX94

|By:, SA News Editor

Soligenix (SNGX.OB) scores an orphan designation for the innate defense regulator SGX94 in patients with acute radiation syndrome.

In clinical models, the drug minimized damage to the skin and gastrointestinal tract, and "enabled clearance of infection as a result of damage to the hematopoietic system." (PR)